A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Eli Lilly and Company
Pfizer
National Cancer Institute (NCI)
Fate Therapeutics
Alterome Therapeutics, Inc.
Hoffmann-La Roche
Erasca, Inc.
Incyte Corporation
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
AstraZeneca
Incyte Corporation
Pfizer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Tizona Therapeutics, Inc
Genentech, Inc.
Revolution Medicines, Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
PAQ Therapeutics, Inc.
Bristol-Myers Squibb
Genentech, Inc.
M.D. Anderson Cancer Center
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Kumquat Biosciences Inc.
Pfizer
Shanghai Zhongshan Hospital
Fate Therapeutics
Massachusetts General Hospital
Eli Lilly and Company
Innovent Biologics (Suzhou) Co. Ltd.
Fate Therapeutics
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Dragonboat Biopharmaceutical Company Limited
M.D. Anderson Cancer Center
Georgetown University
Novartis
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Merck Sharp & Dohme LLC
Masonic Cancer Center, University of Minnesota
GlaxoSmithKline
Yale University
Genentech, Inc.
Bristol-Myers Squibb
University of Chicago
Genentech, Inc.
Merrimack Pharmaceuticals